Today at Berkeley Lab

Global Blood Therapeutics Uses ALS to Tackle Sickle Cell Disease

Sickle cell disease affects millions of people worldwide and is one of the most common genetic disorders in the United States. The most-used therapy for the disease is a cytotoxic drug with additional negative side effects and variable patient response. Bay Area biopharmaceutical company Global Blood Therapeutics is on a mission to develop a better treatment and is using the ALS to help. More>

You can leave a comment. View the Comment Policy.

Leave a Reply